(MENAFN- News Direct) BioVaxys CEO James Passin joins Natalie Stoberman from the Proactive newsroom to discuss the company's acquisition of TAETSoftware, a Vancouver-based clinical studies management company engaged in the development and commercialization of the Trial Adverse Events Tracker (TAET) technology platform. Passin says the acquisition of TAETCO provides BioVaxys with a third low-risk near-term revenue generating product, supporting its core business in cancer and viral vaccine development.--p
< />
MENAFN17032023005728012573ID1105805135
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.